Ivabradina Stada (Ivabradine Hydrochloride)

Ivabradine works by selectively inhibiting the funny (If) current in the sinoatrial node. This action reduces the spontaneous firing rate of pacemaker cells, leading to a lower heart rate without affecting the strength of cardiac contraction or blood pressure.

The appropriate dose of Ivabradina Stada is determined by the prescribing physician based on the patient’s clinical condition, resting heart rate, and response to therapy. Dosage adjustments are made during follow‑up visits to achieve the target heart‑rate range.

Safety data for ivabradine during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and under close medical supervision.

To request Ivabradina Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by targeting the If current without affecting contractility or blood pressure, whereas beta‑blockers act on adrenergic receptors and can reduce contractile force. Ivabradine is often added when beta‑blockers alone do not achieve the desired heart‑rate control.

Store Ivabradina Stada tablets at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the packaging.

Ivabradina Stada is taken orally as a tablet, usually with or without food. The tablet should be swallowed whole with a glass of water, and the dosing schedule set by the prescriber should be followed consistently each day.

The most serious adverse events include atrial fibrillation, severe bradyarrhythmias, and allergic reactions such as rash or angioedema. Patients should seek immediate medical attention if they experience palpitations, fainting, persistent visual disturbances, or signs of an allergic response.

Ivabradina Stada is contraindicated in patients with severe hypotension, sick sinus syndrome, second‑ or third‑degree atrioventricular block, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to ivabradine or any of the tablet’s excipients.